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Human mesenchymal stem cells (hMSCs) are presently being evaluated for their therapeutic potential in clinical studies to
treat various diseases, disorders, and injuries. To date, early-phase studies have indicated that the use of both autologous and
allogeneic hMSCs appear to be safe; however, eﬃcacy has not been demonstrated in recent late-stage clinical trials. Optimized
cell bioprocessing protocols may enhance the eﬃcacy as well as safety of hMSC therapeutics. Classical media used for generating
hMSCs are typically supplemented with ill-deﬁned supplements such as fetal bovine serum (FBS) or human-sourced alternatives.
Ideally, culture media are desired to have well-deﬁned serum-free formulations that support the eﬃcient production of hMSCs
while maintaining their therapeutic and diﬀerentiation capacity. Towards this objective, we review here current cell culture media
for hMSCs and discuss medium development strategies.
1.Introduction
Human mesenchymal stem cells (hMSCs), also referred
to as mesenchymal stromal cells [1], demonstrate regen-
erative properties and multipotentiality, and thus have
been proposed as a potential candidate for cell therapies
and tissue engineering. Clinical studies employing hMSCs
derived from diﬀerent sources have been initiated for the
treatment of several diseases and injuries such as myocardial
infarction, osteogenesis imperfecta, graft-versus-host disease
(GVHD), and Crohn’s disease, spinal cord injury, multiple
sclerosis, and diabetes (http://www.clinicaltrials.gov/). Early-
phase studies with thousands of patients have indicated that
the use of both autologous and allogeneic hMSCs appears
to be safe; however, eﬃcacy has not been demonstrated
in recent late-stage clinical trials [2]. In general, clinical
protocols employ cell culture technologies by which a small
fraction of primary hMSCs are isolated from a selected
tissue source and expanded for multiple passages in order to
generate a clinically relevant number of cells. Consequently,
once the tissue source of hMSCs is determined for an
intended clinical application, the safety and eﬃcacy of cell
therapeutics produced may be signiﬁcantly inﬂuenced by cell
bioprocessing protocols [3]. As a consequence, developing
robust production processes by optimizing culture variables
is critical to eﬃciently and consistently generate hMSCs
thatretaindesiredregenerativeanddiﬀerentiationproperties
while minimizing any potential risks.
Cellculturevariablesincludemediumformulation(basal
media and supplements), culture surface substrate, cell seed-
ing density, physiochemical environment (dissolved oxygen
and carbon dioxide concentrations, temperature, pH, osmo-
lality, and buﬀer system), along with subculture protocols.
In particular, the development of well-formulated culture
media for both the isolation and expansion of hMSCs is
imperative, but has been recognized as an extremely diﬃcult
process due to the high complexity of media formulations.
Herein, we review various types of media that are currently
used for clinical studies or under evaluation, along with the
biological characteristics and ex vivo expansion procedures
for hMSCs. It is clear that deﬁned media optimized for
hMSC isolation and expansion would greatly facilitate the2 Stem Cells International
development of robust, clinically acceptable bioprocesses for
reproducibly generating quality-assured cells. Although sev-
eral serum-free formulations have recently been developed,
the performance of most media seems to be suboptimal.
Identifying critical factors and their concentrations towards
designing an ideally formulated, chemically deﬁned serum-
free medium should be carried out using rational and
systematic approaches. Hence, in the second part of this
paper, we discuss crucial strategies and important decisions
needed for serum-free medium development.
2.Mesenchymal StemCells
2.1. What Is an MSC? Friedenstein and colleagues ﬁrst
reported a small fraction of cells in bone marrow (BM)
attached to and proliferated on tissue culture substrates and
that these cells were able to diﬀerentiate into multiple cell
types such as adipocytes, osteoblasts, and chondrocytes both
in vitro and in vivo [reviewed in [4]]. These cells were
ﬁbroblastic spindle-shaped and readily generated single-cell-
derived colonies and were originally referred to as colony-
forming unit-ﬁbroblasts (CFU-F). Later, these cells were
demonstrated by many investigators to be heterogeneous
populations of nonhematopoietic adult stem/progenitor
cell-like cells residing in marrow stroma and, thus, were
called marrow stromal cells, mesenchymal stem cells, or
multipotent mesenchymal stromal cells [1, 4]. In addition
to BM, similar MSC-like cells have also been shown to
be present in most tissues, including adipose tissue (AT),
synovial membranes, bone, skin, pancreas, blood, fetal liver,
lung, and umbilical cord blood (UCB) [4, 5].
2.2. Characteristics of hMSCs. BM has been the traditional
source of hMSCs for basic research and therapeutic use
because BM harvest is a routine and safe procedure. There-
fore,thecharacteristicsofexvivoexpandedhMSCsdescribed
below mostly represent BM-derived hMSCs unless otherwise
stated.
2.2.1. Morphology. Typically, hMSCs isolated and expanded
in classical FBS-containing media are mostly spindle-shaped
(or fusiform) and cuboidal ﬁbroblast-like cells. More specif-
ically, Prockop and colleagues demonstrated that hMSCs
undergo a time-dependent morphological transition from
thin (small), spindle-shaped cells (considered stem cells or
early progenitors) to wider (larger), spindle-shaped cells
(looked like more mature cells) when cells are plated at
1 to 1,000cells/cm2 [6]. They further showed that the
small, spindle-shaped cells proliferate more rapidly and
have a higher level of multipotentiality, compared to the
slowly replicating large cells, which have lost most of their
multipotentialitybutcanstilldiﬀerentiateintoalineage(e.g.,
osteogenic) as a default pathway. The morphology (and size)
of hMSCs may also be dependent upon culture conditions
(e.g., growth media, culture surface). For example, hMSCs
expanded in bFGF-supplemented media were smaller and
proliferated more rapidly, compared to those in bFGF-
lacking control conditions [7]. Culture surfaces (e.g., treated
with Matrigel) might also aﬀect the morphology [8].
2.2.2. Growth and Adherence Characteristics. hMSCs are
anchorage-dependent cells, which attach to a plastic surface,
spread out, and grow, when maintained in standard culture
conditions (e.g., DMEM supplemented with 10% FBS).
The initial growth of hMSCs in primary BM cell culture
on a plastic surface is characterized by the formation of
single-cell-derived colonies, when the cells are plated at
appropriate numbers. The cells in colonies generated in the
primary culture can typically be subcultured through multi-
ple passages at various plating densities. In general, hMSCs
have great propensity for expansion in culture, although
their proliferation potential is highly variable, depending on
many aspects such as donor age, tissue source, and culture
conditions. For example, Sekiya et al. demonstrated that
hMSCs proliferate more rapidly when passaged by plating
the cells at low densities (e.g., 10–100cells/cm2,c o m p a r e d
to 1,000–10,000cells/cm2)[ 6]. hMSC proliferation is also
highly variable depending on growth media [9].
2.2.3. Immunophenotype. Currently, no prospective markers
exclusively deﬁning hMSCs are available. In general, hMSCs
are negative for hematopoietic surface markers including
Cluster of Diﬀerentiation (CD) 34, CD45, CD14, CD11b,
CD19,CD79α,CD31,CD133andpositiveforCD63,CD105,
CD166, CD54, CD55, CD13, CD44, CD73, and CD90 [10,
11]. However, diﬀerences exist among the studies reporting
the surface marker characteristics, which may be explained
by variations in culture methods and/or diﬀerentiation stage
of the cells [11].
2.2.4. Multilineage Diﬀerentiation Potential. hMSCs have
at least trilineage diﬀerentiation potential in vitro (i.e.,
the ability to diﬀerentiate into bone, cartilage and fat
upon proper induction conditions). This is the most well-
established characteristic of hMSCs and thus is considered
the hallmark of these cells [12]. It has also been observed
that hMSCs could give rise to other mesodermal cells
and nonmesodermal cell types, such as neuron-like and
endoderm-like cells [11].
2.2.5.MinimalCriteriaforDeﬁninghMSCs. Standardculture
protocols for the isolation and expansion of hMSCs have
not been well established, in particular for growth medium.
Therefore, diﬀerent laboratories often use various methods
of isolation/expansion and also diﬀerent approaches to
characterize the cells. This makes it diﬃcult to compare
and contrast the outcomes from various investigators. To
minimize the variations, the Mesenchymal and Tissue Stem
Cell Committee of the International Society for Cellular
Therapy has proposed minimal criteria to deﬁne hMSC
populations. These include the following: (i) hMSCs must
be plastic-adherent when maintained in classical culture
conditions; (ii) hMSCs must express high levels (≥95%
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(≤2% positive) of CD45, CD34, CD14, or CD11b, CD79α
or CD19, and HLA-DR (unless stimulated by interferon-
γ) surface molecules; (iii) hMSCs must diﬀerentiate into
osteoblasts, adipocytes, and chondroblasts under speciﬁc in
vitro diﬀerentiation conditions [10].
2.3. Potential Therapeutic Properties of hMSCs. hMSCs show
various properties that could be important in therapeutic
applications. Indeed, some of these functions are currently
being exploited in clinical trials with great promise.
2.3.1. Multipotentiality. As described earlier, hMSCs can
diﬀerentiate into distinctive mesenchymal phenotypes, and
thus they have been used to reconstruct damaged tissues
upon transplantation in association with scaﬀolds. In addi-
tion, due to their diﬀerentiation potential into nonmeso-
dermal cell types, hMSCs cells have also been proposed for
replacement therapies to treat various diseases and disorders
such as neuronal diseases and diabetes [13, 14].
2.3.2. Tropism for Sites of Disease. hMSCs appear to be
capable of homing to sites of disease or damage. It has been
reported that hMSCs systematically infused into diabetic
mice migrated to damaged sites (i.e., pancreatic islets and
renal glomeruli) and contributed to the repair of tissue [15]
by certain mechanism(s) yet unidentiﬁed.
2.3.3. Secretion of Bioactive Factors. hMSCs inherently syn-
thesize and secrete a broad range of bioactive agents
such as cytokines and growth factors [16]. This intrinsic
secretory activity of hMSCs may signiﬁcantly contribute to
tissue repair or regeneration, presumably by establishing a
regenerative microenvironment at sites of tissue injury or
damage [16]. Originally, therapeutic eﬀects observed with
the use of hMSCs were thought to be due to their transd-
iﬀerentiation (i.e., diﬀerentiation into nonmesodermal cell
types) potential. However, these beneﬁcial eﬀects were often
demonstrated without evidence for the engraftment and
transdiﬀerentiation of transplanted hMSCs in animal model
studies. Therefore, these indirect, secretory functions of
hMSCs have been proposed as an alternative mechanism
explaining the therapeutic eﬀects, and importantly, these
characteristics have generated clinical interest to use undif-
ferentiated hMSCs for various applications such as repair or
regeneration of damaged tissues [16].
2.3.4. Immunomodulation. hMSCs also display immune
regulatory properties that might represent a critical role
in the therapeutic application of these cells [17]. In vitro
studies using hMSCs demonstrated that these cells suppress
the proliferation of T cells. Further, it was also revealed
that hMSCs inhibit the diﬀerentiation and maturation
of dendritic cells (DCs) and decrease the production of
inﬂammatory cytokines by various immune cell populations
[18].DCsarethemostpotentantigen-presentingcells,which
specialize in antigen uptake, transport, and presentation and
have the unique capacity to stimulate na¨ ıve and memory
T cells [17]. In addition to the in vitro eﬀects, it has
been seen in animal model studies that hMSCs may also
display immunosuppressive capacities in vivo.F o re x a m p l e ,
hMSCs facilitated engraftment of hematopoietic stem cells
and prolonged skin allograft survival [19]. Further, it has
been demonstrated that the use of hMSCs reversed severe
acute GVHD [19]. However, while in vitro results con-
sistently show the immunosuppressive capacity of hMSCs,
studies in animals and humans suggest that hMSCs are
less eﬀective in producing systemic immunosuppression
in vivo [20]. Therefore, further studies using standardized
hMSC populations are urgently needed to verify their in
vivo immunosuppressive potential and to deﬁne the optimal
conditions for the use of hMSCs as immunotherapy.
2.3.5. Immune Privileged or Hypoimmunogenic Property.
When undiﬀerentiated hMSCs were transplanted into recip-
ients in preclinical and clinical trials, these cells produced
various cytokines and growth factors and had an ability to
modify the response of immune cells. Another important
observation is that hMSCs escape immune recognition or at
least possess a hypoimmunogenic character upon allogeneic
transplantation [21]. Indeed, clinical studies showed that
hMSCs evoke little or no immune reactivity in allogeneic
recipients [5]. This indicates that, in addition to the trans-
plantation of autologous cells to patients to minimize the
risk of immune response, allogeneic hMSCs could also be
safely used. If this is the case, the use of allogeneic hMSCs
has an important advantage in that the culture-expanded
cells could be considered as an “oﬀ the shelf” therapeutic
product. Indeed, clinical studies using allogeneic, as well as
autologous, hMSCs from BM have been initiated for the
treatmentofseveraldiseasesandinjuriessuchasosteogenesis
imperfecta, GVHD, leukemia, myocardial infarcts, Crohn’s
Disease, cartilage and meniscus injury, stroke, and spinal
cord injury [5, 16].
2.4. Safety of Using hMSCs. A large body of safety data
has been gained from the use of hMSCs in various clinical
applications including the treatment of GVHD and the
facilitation of BM engraftment [14]. That is, until present,
only few adverse eﬀects attributed to hMSC transplantation
have been reported [22]. This has facilitated the rapid
translation of basic research into clinical trials. However,
there are some obvious issues that need to be addressed
before the wide implementation of clinical trials using
hMSCs.
2.4.1. Tumor Formation. In general, it is considered that
hMSCs can be safely cultured in vitro with no risk of
malignant spontaneous transformation [23]. Stenderup and
colleaguesculturedseveral strains of hMSCs fromBM at var-
ious ages (i.e., aged 18–81 years) until the cells reached their
maximal life span without any evidence of transformation
[24]. Further, there have been no reports with human trials
demonstratingtheformationoftumorsbyculture-expanded
hMSCs [22]. Nonetheless, a potential risk for spontaneous
transformation associated with hMSC proliferation in vitro,
in particular after long-term culture, cannot be ruled out.4 Stem Cells International
The transplantation of primitive stem/progenitor cells with
considerable proliferative potential can raise the possibility
of tumor formation, and any ex vivo manipulation will
increase the chances of transformation [14]. It has been
recommended by the Food and Drug Administration (FDA)
that “minimally manipulated” cells be used for human
clinical trials. In this regard, attempts are being made to
develop an eﬃcient production system to produce clinically
relevant numbers of hMSCs at relative shorter periods of
time with lower passage numbers [25].
2.4.2. Promotion of Tumor Growth and Development. A
potential risk of treatment with hMSCs can paradoxically
arise from the fact that these cells are capable of suppressing
various immune cells, which may promote tumor growth
andmetastasis.TheroleofhMSCsintumorsiscontroversial:
some studies have demonstrated enhancement of tumor
growth and metastasis, while others have shown no apparent
eﬀect or inhibition of tumor growth with the use of hMSCs
[26].
2.4.3. Immune Response. Although hMSCs themselves
appear to escape immune recognition, those “cultured in
medium containing FBS” can produce immune reactions
in patients receiving repeated administrations of these
cells [27]. Conventionally, the optimal conditions for
hMSC expansion require media supplemented with FBS
at a concentration of 10–20%, which corresponds to
approximately 5–10mg FBS proteins/mL of medium. Spees
et al. demonstrated that, when hMSCs were cultured in
medium containing 20% FBS and harvested, 7–30mg of FBS
proteins were still associated with a standard preparation of
100 million hMSCs, a dosage that probably will be needed
for clinical therapies [28]. Thus, immunological reactions
causedbymedium-derivedFBSproteinswillbeaconcern,in
particular for certain types of cell therapy involving multiple
administrations of hMSCs. The safety issue associated with
theuseofFBSinculturemediawillbeavoidedbydeveloping
an alternative culture protocol to produce hMSCs in vitro in
the absence of FBS.
2.5. Sources of hMSCs. Although the traditional source of
hMSCs is BM, it has been demonstrated that cells displaying
similar characteristics with BM-hMSCs can also be derived
from other sources including AT, UCB, umbilical cord tissue,
placenta, amniotic ﬂuid, liver, lung, pancreas, and muscle
[29–34]. The ideal source of hMSCs for therapeutic use
would be one that is readily available and can be expanded in
culture rapidly to yield large numbers of cells. In this regard,
hMSCs from readily obtainable tissue otherwise discarded,
such as AT, may oﬀer a preferable alternative to BM, because
the collection of BM is an invasive procedure. Moreover, AT
is a source of abundant hMSCs, and the AT-derived hMSCs
have shown various potential therapeutic properties both
in vitro and in vivo [29]. UCB, umbilical cord tissue, and
placenta also represent attractive sources of hMSCs because
these tissues are readily available and the derived cells may
contain less genetic abnormalities and greater proliferative
capacity than adult tissue-derived hMSCs [30–32].
It is important to note that there is much evidence
demonstrating that hMSCs (or similar populations) derived
from various sources showed diﬀerent characteristics in gene
expressionproﬁle,proliferationanddiﬀerentiationpotential,
and functional properties although most of these satisﬁed
the minimal criteria for deﬁning MSCs and, thus, were
considered as hMSCs as a whole [35–38]. For example,
studies have shown that AT-hMSCs exhibited in vitro
immunomodulatory properties at higher eﬃciencies, com-
pared to BM-derived counterparts [35]. Another example
can be found from a study comparing the diﬀerentiation
potential of hMSCs from BM and pancreas into insulin-
producing endocrine cells [36]. This study revealed that
hMSCs derived from the pancreas are committed to an
endocrine fate and thus have a greater propensity to generate
insulin-producing cells compared to BM-hMSCs. Therefore,
to select an ideal source of hMSCs for therapeutic use,
their functional properties (e.g., diﬀerentiation potential,
immunomodulation, secretion of bioactive factors) should
be critically evaluated in comparison with those from other
potential sources, in addition to the availability of tissue and
cell proliferation capacity as mentioned earlier.
3. Generation of Mesenchymal Stem Cells
3.1. hMSC Number. T h ef r e q u e n c yo fh M S C si nB Mi s
very low. The CFU-F assay is widely used to estimate the
number of MSCs in primary BM cells as well as passaged
cell populations in culture [39, 40]. Using this assay, it
has been reported that MSCs represent 0.01% to 0.001%
of human BM mononuclear cells (MNCs) [39]. It was
also demonstrated that hMSCs comprise approximately 1
in 10,000, 100,000, and 250,000 BM-hMNCs of newborns,
teens, and 30 year-olds, respectively, indicating that the
hMSC frequency is highly variable with age [16].
There is a signiﬁcant diﬀerence in the frequency of
hMSCs present in other tissues/organs, heavily depending
on the source. Kern et al. reported diﬀerent frequencies of
hMSCs in BM, AT, and UCB. In their study, with culture-
initiating populations (i.e., MNCs of BM and UCB, and
stromalvascularfractionofAT),itwasdemonstratedthatthe
numberofCFU-Fs(i.e.,correspondingtohMSCs)calculated
at the basis of 1 × 106 initially plated cells was highest for AT
(557),followedbyBM(83)[37].Incontrast,thefrequencyof
CFU-FsinUCBwasconsiderablylower.Similarobservations
were reported by others [41, 42].
Although the dosage of hMSCs for their optimal use
in therapeutic applications is still unclear and should be
dependent upon the type of cell therapy, at least 1 to 2 ×
106 hMSCs per kg body weight of the adult patient is
generally suggested [43]. Consequently, the number of
primary hMSCs, regardless of the sources, is insuﬃcient for
researchaswellasclinicaluse.Hence,itisnecessarytoisolate
hMSCs and then subsequently expand them for multiple
passages on tissue culture substrates in order to generate
clinically relevant numbers of cells.Stem Cells International 5
3.2. Isolation and Expansion of hMSCs
3.2.1. Isolation of hMSCs (Primary Culture). As there are no
universal surface markers available for exclusively deﬁning
hMSCs, these cells have traditionally been isolated from
initialprimarycellfractions(e.g.,BMMNCs),basedontheir
selectiveadherence,comparedtohematopoieticcells,toplas-
tic surfaces. Therefore, the hMSCs obtained are intrinsically
heterogeneous. Importantly, it has been demonstrated that
thecharacteristicsofisolatedcellsarehighlydependentupon
culture conditions used. For BM cells, either unfractionated
whole BM, fractionated MNCs by density gradient, or
separated cells by depletion of certain subpopulations are
used, with the fractioned MNCs being the most popular.
3.2.2. Expansion of hMSCs. As a large number of hMSCs
is needed for their clinical use, cells obtained from the
primary culture are further expanded through multiple
passages. Typically, hMSCs obtained from young donors
can undergo 24–40 population doublings (PD) in culture
before they reach senescence, while those from older donors
retain reduced proliferative potential [11]. Similar to other
diploid cells, hMSCs grow at a rather constant rate during
early passages (typically for the ﬁrst 2 to 3 weeks) and
then with a gradual increase in cell doubling times as the
passage number increases until the growth ceases due to
senescence[11].Itisalsoknownthat,aftertheinitialculture,
hMSCs progressively show loss of multipotentiality [44]
under classical media and possibly other culture conditions.
3.3. Culture Media for hMSCs
3.3.1. Classical FBS-Based Media. Conventional media used
forisolatingandexpandinghMSCsincludesupplementation
of FBS at 10–20% (v/v). FBS contains a high content of
attachment and growth factors as well as nutritional and
physiochemical compounds required for cell maintenance
and growth. The function and characteristic of serum is
further reviewed later in this paper. FBS-based media remain
a common standard in generating hMSCs for basic research
and clinical studies; however, the use of FBS is not desirable,
raising several safety and other concerns. The inherent
potential problems associated with the ill-deﬁned FBS and
other animal-derived supplements are as follows [45–47]:
(i) risk of contamination associated with harmful
pathogens such as viruses, mycoplasma, prions, or
unidentiﬁed zoonotic agents and transmissions of
these contaminants to cells being used for cellular
therapy,
(ii) high content of xenogeneic proteins that can be asso-
ciated with cell therapeutics during culture, causing
concerns relating to immune reaction in patients, as
described earlier,
(iii) high degree of batch-to-batch variation causing
inconsistency in the generation of quality-assured
cells and thus making standardization of the produc-
tion process diﬃcult,
(iv) presence of growth inhibitors, cytotoxic substances,
and/or diﬀerentiation agents. (Beyond its growth-
promoting property, serum may also contain com-
ponents that are inhibitory for the growth of certain
cell types. It has been demonstrated that some cell
types cannot be cultured in the presence of serum
at its typical concentrations in medium due to its
unidentiﬁed cytotoxic constituents. It is also well
known that serum is toxic at high concentrations for
most cell types [48]),
(v) requirement of a set of strict quality controls to
minimize the risk of contamination and to select
appropriate FBS lots supporting growth of cells
while retaining their regenerative and diﬀerentiation
properties,
(vi) interference of unidentiﬁed factors on the eﬀect of
hormones, growth factors, or other additives under
investigation,
(vii) limited availability,
(viii) ethical issues [49].
Considered together, despite strict selection and testing
for safety and growth-promoting capacity, the use of FBS
represents a major obstacle for the wide implementation of
hMSC-related therapies.
3.3.2. Humanized Media. In order to alleviate the safety and
regulatory concerns raised by the use of animal serum for
generating hMSCs, autologous or allogeneic human blood-
derived materials, including human serum, plasma, platelet
derivatives (e.g., platelet lysate), and cord blood serum, are
currently under investigation for their clinical utility as an
alternative medium supplement.
Human autologous serum has been reported to support
hMSCexpansion[50–53].Itwouldbeproblematic,however,
to acquire amounts suﬃcient to generate clinically relevant
n u m b e r so fh M S C s .M o r e o v e r ,t h eu s eo fa u t o l o g o u ss e r u m
may not be applicable for elderly patients as its capacity
to support cell growth may decrease with their age. The
performance of human allogeneic serum from adult donors
is rather controversial because contradictory results have
been reported [52, 54–58]. Allogeneic human serum from
UCB [59, 60] and placenta [61] has also been proposed as
potential alternatives to replace FBS because these primitive
t i s s u e sa r ear i c hs o u r c eo fg r o w t hf a c t o r s[ 49].
Attempts have also been made by many investigators to
examine the utility of human platelet lysate (hPL), which
has been prepared by mechanical disruption or chemical
lysis of the platelet membrane [49], for the cultivation
of hMSCs. Most of the studies reported that the growth
factor-enriched allogeneic hPLs have considerable growth-
promoting properties for hMSCs while maintaining their
diﬀerentiation potential and immunomodulatory properties
[62–70]. However, some other studies reported data that
showed a reduction of osteogenic or adipogenic diﬀeren-
tiation potential when hMSCs were cultured in hPL-based
media [67, 71]. Moreover, a recent report illustrated that,
although cell proliferation was greatly enhanced, the use of6 Stem Cells International
hPL (supplemented into RMPI 1640 medium) altered the
expression of some hMSC surface molecules and led to a
decrease in their in vitro immunosuppressive capacity [72].
This study also showed that the production of prostaglandin
E2, which has previously been demonstrated to play a major
role in the suppression of immune cells [73], was lowered
under the use of hPL compared to FBS.
Although considered relatively safer than FBS for human
therapeutic applications, the use of human-sourced sup-
plements is still a matter of substantial debate, prompting
some concerns [74, 75]. There is a risk that allogeneic
human growth supplements may be contaminated with
human pathogens that might not be detected by routine
screening of blood donors. Moreover, these crude blood
derivatives are poorly deﬁned and suﬀer from batch-to-
batch variation, and thus their ability to maintain hMSC
growth and therapeutic potentials could be widely variable.
Inparticular,thevariabilitycanbeasigniﬁcanthindrancefor
implementingtheclinical-scaleproductionofhMSCssimply
because it could make it diﬃcult to obtain cells retaining
desired qualities in a consistent and predictable manner,
which is crucial for minimizing treatment failures.
3.3.3. Deﬁned Serum-Free Media. The concerns raised from
the use of ill-deﬁned serum or human-sourced supplements
demonstratethe need forthe development ofdeﬁned serum-
free media. While reducing the problems associated with
such crude materials, deﬁned serum-free media may further
provide additional advantages as follows.
(i) Deﬁned formulations designed to support the gen-
eration of a population enriched with a desired cell
type (i.e., hMSCs) while preventing overgrowth of
undesired cells in primary cultures will lead to the
production of more homogeneous hMSCs (i.e., more
precisely, a population of adherent cells containing
a high content of colony-forming multipotent mes-
enchymal cells). It has been shown that medium
formulations greatly aﬀect the frequency and size of
colonies in the primary and passaged hMSC culture,
and a systematically optimized deﬁned medium for
hMSCs led to signiﬁcant increased colony-formation
compared to FBS-based cultures [76].
(ii) The well-deﬁned nature of the medium would facil-
itate enhancing cell bioprocessing protocols, which
may be crucial for increasing clinical eﬃcacy by
producing cells with desired properties. For instance,
based on the proposed mechanism that hMSCs
exert therapeutic beneﬁts via the secretion of certain
soluble molecules, the medium formulations may
need to be modiﬁed to enhance expression of speciﬁc
genes to achieve an optimal cytokine proﬁle [3].
(iii) When ex vivo diﬀerentiated cells are desirable for
therapeutic use, the transition of an expansion state
to a diﬀerentiation phase under deﬁned conditions
could facilitate the production of such desired cell
types in a more favorable and controllable environ-
ment. Davani et al. demonstrated that, in an eﬀort
to diﬀerentiate hMSCs (pancreas-derived) to insulin-
expressing cells, the shift of a serum-based expansion
condition to a serum-free diﬀerentiation condition
led to considerable cell death [36]. In principle, it
may be less harsh to cells to switch only key “growth-
promoting factor(s)” to “diﬀerentiation-inducing
factor(s)” while maintaining the base condition.
Attempts have been made to develop deﬁned serum-free
media for animal or human MSC growth; however, most
of them have demonstrated only limited performance [77–
80]. These media formulations were only shown to support
cell expansion for single-passage cultures or at slow rates
through multiple passages. Moreover, all of these studies
used cells which had previously been exposed to serum
during the initial isolation/expansion phases. Serum-derived
contaminants are probably carried over with the cells when
they are placed under serum-free conditions after exposure
to serum, and thus, exposure to serum may ultimately limit
their therapeutic use.
The ideal media should consist of chemically deﬁned
constituents that support the attachment and growth of
hMSCs primary cultures as well as passaged cultures,
while maintaining their therapeutic properties. Towards
this objective, our group has recently carried out a study
to identify key attachment and growth factors required
for both primary and passaged cultures, and this study
led to the development of a deﬁned serum-free medium
(PPRF-msc6) for hMSC isolation and expansion [76]. We
demonstrated that PPRF-msc6 medium supported the gen-
eration of hMSCs from multiple BM samples in a rapid
and consistent manner, maintaining their multipotency and
hMSC-speciﬁc immunophenotype. Furthermore, compared
to a classical serum-supplemented media (i.e., DMEM sup-
plemented with prescreened FBS), hMSCs cultured in PPRF-
msc6 exhibited numerous advantages from a production
standpoint. Speciﬁcally, these hMSCs had a greater colony-
forming capacity in primary as well as passaged cultures,
negligible lag phase and explicit exponential growth, lower
population doubling times (21–26h versus 35–38h; between
passage levels 1 and 10), a greater number of population
doublings (62 ± 4v e r s u s4 3± 2; over a two-month period),
andamorehomogeneouscellpopulation, whichwassmaller
in size [81]. Consequently, the sustained production of
smaller hMSCs in a rapid manner requires less time and
surface area to obtain clinically relevant numbers of hMSCs,
while reducing risk of contamination and saving cost and
labor. Moreover, from a therapeutic viewpoint, the size of
cells to be transplanted into patients could be an important
issue because it has been shown in animal-model studies
that most of hMSCs grown in FBS-supplemented media
were trapped in the lung [82]. Small hMSCs may oﬀer
a signiﬁcant beneﬁt in transplantation therapies because
the small cells may travel through the lung and home
to the site of injury or disease at high eﬃciencies [83].
Similar to the performance with BM cells, PPRF-msc6 also
allowed for the isolation and extended expansion of hMSCs
from other sources, including AT and pancreatic tissue
samples, more rapidly and eﬃciently compared to controlStem Cells International 7
FBS-supplemented media [our unpublished data]. In view
of the “deﬁned” status, PPRF-msc6 contains some serum
components, such as insulin, transferrin, serum albumin,
and fetuin, which are often associated with traces of other
serum constituents, and thus further investigations need to
be conducted to reﬁne this medium to a true chemically
deﬁned medium by replacing these components with syn-
theticalternatives.Recently,forinstance,wehavesuccessfully
replaced native insulin with a recombinant insulin without
any decrease in the performance of PPRF-msc6 for hMSC
culture. The replacement of native transferrin, albumin,
and fetuin in this medium with recombinant alternatives
or other supplements is currently underway. Nonetheless,
PPRF-msc6 represents the most well-deﬁned serum-free
formulation to support both the isolation and expansion of
hMSCs in the literature to date and a signiﬁcant step forward
for producing hMSC therapeutics. The protocol for PPRF-
msc6 preparation has been described in detail [76] so that
the disclosed formulation or its modiﬁcations can be further
d e v e l o p e db ya n yi n t e r e s t e dp a r t y .
Eﬀorts have also been made to test or modify existing
deﬁned medium formulations designed for other stem cell
types in order to cultivate hMSCs. Rajala et al. illustrated
thatadeﬁned,xeno-freemediumforhumanembryonicstem
cells (hESCs) allowed, during a single-passage culture, the
expansion of hMSCs previously isolated from AT samples in
the presence of allogeneic human serum [84]. This study did
not report whether this medium supported the growth of
hMSCs in primary culture as well as through multiple pas-
sages. Also, Mimura et al. modiﬁed a deﬁned hESC medium
to promote the expansion of an immortalized genetically
modiﬁed hMSC line [85]. The cells grown in their disclosed
medium formulation demonstrated diﬀerentiation capacity
towards osteogenic and adipogenic lineages while displaying
a rather diﬀerent gene expression proﬁle compared to those
cultured in FBS-based medium.
3.3.4. Commercially Available Media for Expanding hMSCs.
Several commercially available serum-free media have
recently been introduced for the expansion of hMSCs
[reviewed in [86]]. StemPro MSC SFM from Invitrogen rep-
resents the ﬁrst commercial serum-free medium that allows
the isolation and expansion of hMSCs from BM and has
recently been cleared by the FDA as a medical device for clin-
ical trials in the United States (http://www.invitrogen.com/).
Agata et al. demonstrated that this medium supported
hMSC growth more rapidly at early passages while reaching
senescence earlier (at passage 5) with gradually reduced
proliferation rate, compared to a control FBS medium [87].
In addition, although most of the hMSC-speciﬁc surface
antigens were expressed on both cell populations expanded
in the serum-free medium and an FBS-based reference
medium, some molecules were expressed in diﬀerent levels
(i.e., CD105 and CD146). Moreover, it appears that both
cell populations displayed diﬀerent levels of stemness as
well as diﬀerent diﬀerentiation potential (i.e., cells expanded
in serum-free medium exhibited lower ALP activity in
noninduced state, but a greater response to osteogenic
induction compared to serum-based controls). In summary,
this commercial serum-free medium seems to generate
h M S C sw i t hd i ﬀerent characteristics in comparison with
those derived in classical FBS media.
Aiming towards the widespread implementation of
hMSC-related therapy in later stage of clinical trials, serum-
free, xeno-free media for hMSC culture have also been com-
mercialized. However, the formulations of these commercial
media are not disclosed, which may restrict their wide utility
in hMSC research and clinical studies. The identiﬁcation
of speciﬁc medium components allowing for the serum-
free isolation and expansion of hMSCs would contribute
signiﬁcantly to the research and therapeutic applications of
these cells. Moreover, as medium formulations determine
cell characteristics (i.e., growth pattern, gene expression,
phenotype, and functional properties), it is important to
evaluate carefully each of these commercial media for
intended therapeutic applications, preferably in parallel to
select the best choice for each speciﬁc target.
We have recently initiated a study to compare these com-
mercial media along with other existing media. The media
under investigation include Mesencult-XF (STEMCELL
Technologies), StemPro MSC SFM Xeno-Free (Invitrogen),
MSCGM-CD (Lonza), PPRF-msc6, and DMEM +10% FBS
(Lonza). Our initial data show that the performance of the
commercial hMSC media on the attachment and growth of
primaryBM-hMSCsisquestionableandthusshouldbeopen
to discussion. Speciﬁcally, in a preliminary experiment, the
commercial media were evaluated in parallel with PPRF-
msc6 and 10% FBS DMEM by plating human BM MNCs
into human ﬁbronectin-coated T-25 ﬂasks containing each
of the media. Cells were inoculated at 150,000cells/cm2,a n d
nonadherent cells in each medium were removed after 60
hours with 100% medium change. Thereafter, the adherent
cells were allowed to grow with 50% medium replacement
every other day, and then stained on day 12. In this
experiment, none of the commercial media demonstrated
cell growth (Figures 1(a)–1(c)). In contrast, a signiﬁcant
number of well-developed colonies were found in the culture
with PPRF-msc6 (Figure 1(d)). The serum-based control
culture with 10% FBS DMEM also resulted in the formation
of colonies although most of them were still premature.
Lindroos et al. reported that StemPro MSC SFM Xeno-Free
medium provided signiﬁcantly higher proliferation rates of
AT MSCs when compared with serum-containing media
[88]. In their study, however, the authors tested the com-
mercial serum-free medium using cells that were previously
isolated and expanded in a serum-containing medium (10%
human serum), and the ability of StemPro MSC SFM Xeno-
Free medium to allow the growth of primary hMSCs was
not addressed. Moreover, Hartmann et al. stated that they
were not able to culture hMSCs derived from the UC tissue
usingStemProMSCSFMXeno-Freemediumwithoutserum
[73]. In contrast, the authors demonstrated that Mesencult-
XF medium supported the isolation and expansion of
UC-hMSCs without the use of serum. In an attempt to
culture hMSCs from BM using a xeno-free protocol (i.e.,
proprietary Mesencult-XF Attachment Substrate as well
as medium), Miwa et al. also showed that the use of8 Stem Cells International
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Figure 1: Cultivation of primary human BM MNCs using diﬀerent media including three commercial media. Cells were inoculated at
150,000 BM MNCs/cm2 into ﬁbronectin-coated T-25 ﬂasks, each containing 8mL of Mesencult-XF (a), StemPro MSC SFM Xeno-Free (b),
MSCGM-CD (c), and PPRF-msc6 (d), and a classical FBS medium (10% FBS DMEM) (e). After 60h, nonadherent cells in each medium
were removed, and fresh medium was added to the adherent cells (100% medium change). The adherent cells were allowed to grow for
additional 10 days with 50% medium change every other day, and then stained with crystal violet to visualize colonies generated.
Mesencult-XF medium resulted in the growth of primary
BM-hMSCs more rapidly than a serum-containing medium
[89].
The contradictory data between our work and the
literature [73, 89] regarding Mesencult-XF medium may
be due, at least in part, to the use of diﬀerent substrate
materials. Speciﬁcally, we used human ﬁbronectin-coated
ﬂasks, while Miwa et al. used a proprietary substrate-coating
product. In this regard, we plated the nonadherent cells,
which were removed from the ﬁrst medium change during
theprimaryculturewitheachmediumdescribedearlier,into
new ﬂasks containing the same medium to allow them to
attach to the new substrate and grow. For convenience, here
we call these as “secondary” cultures as opposed to their
original cultures described in the previous paragraph and
Figure 1. The “secondary” ﬂasks were coated with gelatin
(bovine), which is widely used to facilitate the attachment
of many types of anchorage-dependent cells to the substrate.
In these secondary cultures, we observed that a number
of colonies were formed in the culture with Mesencult-
XF medium (Figure 2(a)). Together with the data obtained
from the original culture (Figure 1(a)), this demonstrates
the ability of Mesencult-XF medium to allow the growth of
primary hMSCs, but implying that the performance of the
medium could be improved by manipulating the substrate-
coating materials. In contrast, StemPro MSC SFM Xeno-
Free medium and MSCGM-CD medium did not allow for
colony formation (Figures 2(b) and 2(c), resp.). These data
suggest that factors required for the isolation of hMSCs from
primary cultures seem to be missed in both media. Similar
with the study by Hartmann et al. [73], we also observed
that the addition of low serum (i.e., 2% prescreened FBS)
into StemPro MSC SFM Xeno-Free medium (and MSCGM-
CD medium) supported the growth of primary BM-hMSCs
(data not shown). Based on these observations, therefore, we
would argue that it should be desirable to further optimize
all the commercial media described here for the serum-
free, xeno-free isolation of hMSCs. Regarding PPRF-msc6,
beyond the high number of large colonies generated in the
original culture (Figure 1(d)), a number of colonies also
appeared in the secondary cultures (Figure 2(d)), which
were initiated with the nonadherent cells that had been
normally discarded in our previous work [81]. In contrast,
the FBS-based culture led to the appearance of only a few
colonies in its secondary culture (Figure 2(e)), indicating
that the majority of hMSCs obtainable from the use of 10%
FBS DMEM attached to the surface of original culture in
the presence of known and unknown attachment factors
included in serum. Considered together, these data imply
that the yield of hMSCs obtained from the primary culture
of BM cells with PPRF-msc6 could further be increased by
modifying the culture protocols, particularly by identifying
optimal attachment factors and/or substrate-coating materi-
als to enhance initial cell attachment eﬃciencies.
A commercial medium (mTeSR) with disclosed compo-
sition, which was originally developed for the expansion of
hESCs, has also been tested for hMSC culture [90]. Although
this deﬁned medium together with human ﬁbronectin-
treated substrate allowed the expansion of BM-hMSCs pre-
viously isolated using FBS-based medium, it did not support
cell growth in primary BM cultures. In addition, when
hMSCs were plated into the mTeSR at a very low density
for a CFU-F assay, the colonies derived were signiﬁcantly
smaller at lower frequency, compared to a control case
with FBS-based medium. Moreover, mTeSR-derived cells
demonstrated signiﬁcantly decreased adipogenic potential.
Therefore, further studies should be carried out with this
medium to identify factors aﬀecting multipotency as well as
growth of hMSCs to make the disclosed formulation viable
for research and clinical applications.
In summary, although numerous deﬁned hMSC media
are commercially available or have been introduced inStem Cells International 9
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Figure 2: Cultivation of nonadherent cell fractions removed from the culture of primary BM MNCs in diﬀerent media. Nonadherent cells
and spent medium removed from each of the ﬂasks, demonstrated in Figure 1, were replated into a new T-25 ﬂask coated with gelatin
containing 4mL of the fresh medium—that is, Mesencult-XF (a), StemPro MSC SFM Xeno-Free (b), MSCGM-CD (c), PPRF-msc6 (d), and
10% FBS DMEM (e). After 60h, nonadherent cells and medium in each ﬂask were discarded, and fresh medium was added to the adherent
cells (8mL per ﬂask). The adherent cells were allowed to grow for additional 8 days with 50% medium change every other day and then
stained with crystal violet to visualize colonies generated.
the literature to support the growth of hMSCs, one must
realize that the therapeutically relevant properties of culture-
expanded hMSCs could be signiﬁcantly aﬀected by medium
components. Considering the safety and eﬃcacy required
to produce hMSC therapeutics for intended clinical appli-
cations, it is crucial to compare diﬀerent media (and their
formulations if the recipe is disclosed) and probably further
optimize the formulations in a systematic manner. In this
regard, the disclosed medium formulations for hMSCs (e.g.,
those reported in [76, 80, 85, 90]) are best positioned to
be further developed by the many investigators interested in
therapeutic applications of hMSCs.
4. Development of Deﬁned Serum-FreeMedia
Deﬁned serum-free medium development or optimization
for a speciﬁc cell type is a very complicated process because
multiple variables that aﬀect the maintenance, growth, and
characteristics of cells are interrelated. Moreover, designing a
new serum-free formulation for anchorage-dependent cells
such as hMSCs tends to be more fastidious compared to
those grown in suspension culture, as the interaction of cells
with the substrate on which they attach and spread prior
to growth needs to be understood. Medium development
studies should involve rational approaches: (i) to select
appropriate factors (e.g., basal medium formulations and
growth/attachment proteins) and (ii) to screen them in a
stepwise,systematic mannerfortheireﬀectoncellproperties
and growth.
4.1. Cell Culture Requirements. An understanding of the
requirements for successful cell culture is a prerequisite for
designing a rational strategy towards the eﬃcient develop-
ment/optimization of a new serum-free medium. In addi-
tion, since anchorage-dependent hMSCs normally require
serum,namely,someserumcomponentsyetunidentiﬁedbut
responsible for their attachment, spread, and growth, it is
particularly crucial to understand the functions that serum
serve in cell culture in order to identify such components.
Hence, speciﬁc requirements of nutrients and nonnutrient
elements for cell culture are brieﬂy reviewed below with a
special emphasis on the constituents and functions of serum.
4.1.1. Nutrients. Nutrients refer to chemical substances that
are taken into cells and utilized as substrates in energy
metabolism or biosynthesis, as catalysts in those processes,
or as structural components of cellular organelles. The
nutrients are divided into organic nutrients, inorganic salts,
and trace elements, and the organic nutrients are further
subdivided into amino acids, carbohydrates, lipids, vitamins,
and others [91]. Generally, the nutrients are considered
as the “deﬁned” portion of culture media. In addition
to the “nutrient” roles, the nutrients also have regulatory
functions. It has been demonstrated that these nutrients
could represent the only requirements for in vitro growth of
certain transformed cell lines [92]; however, more fastidious
nontransformed normal cells typically require additional
growth-promoting supplements for their growth in culture.
Organic Nutrients. Amino acids represent essential elements
ofmediaasbuildingblocksforproteinsynthesis.Inaddition,
certain amino acids have other key roles in multiplication
of cells in culture, especially under serum-free conditions.
In particular, glutamine appears to play major roles in
manymetabolicpathways,andthusanadequateextracellular
concentration of glutamine is typically needed in cell culture
media. It is common to add 2–4mM of glutamine to hMSC
media. It is important to note that glutamine is labile under
cell culture conditions, and thus the amount of glutamine
for hMSC culture should be determined considering both10 Stem Cells International
the requirement for cell growth and its breakdown during
the culture. Moreover, nonessential amino acids have been
added into a deﬁned medium developed for hMSC growth
[80].
A carbohydrate source is essential for the growth of cells
in culture, since neither amino acids nor fats can readily
be used either as the sole energy source or as substrates
to build up a suﬃcient pool of intracellular carbohydrate
intermediates. Glucose is the commonly provided source of
energy for cells in culture, and together with amino acids it
is included in most deﬁned basal medium formulations. It
is known that glucose at high concentrations has harmful
eﬀects on some cell types in culture. For this reason, low
concentrations of glucose (∼5mM) are commonly used
for hMSC culture. However, recent evidence reveals that
high glucose concentrations (∼25mM) led to comparable or
higher growth of animal and human MSCs [93–95].
It is known that certain lipids, such as cholesterol,
free linoleic acid and its metabolites, free oleic acid, and
phospholipids containing linoleic acid, stimulate growth of
mammalian cells. Lipids are frequently not included in the
deﬁned portions of cell culture media. Large amounts of
bound lipids are contained in serum; therefore, normally
serum-containing media do not need the supplementation
of additional lipids. In contrast, externally supplied lipids
are generally required in serum-free culture [91]. Lipid
supplements have been added to serum-free media for
hMSCs [76, 80].
In general, mammals require 12 vitamins, including the
4 fat-soluble vitamins (A, D, E, and K) and the 8 members
of the B complex (thiamine, riboﬂavin, niacin, pyridoxine,
pantothenic acid, folacin, vitamin B12, and biotin). In
addition, primates, guinea pigs and ﬂying mammals require
vitamin C (ascorbic acid). In contrast, normal diploid cells
in culture exhibit requirements for the B vitamins, while
some cells have shown growth responses to ascorbic acid.
For this reason, most cell culture media include all the B
vitaminsbutvariablycontainvitaminC[91].Othervitamins
are not included in media. The B vitamins function as
cofactors for speciﬁc enzymes, and their deﬁciency can result
in death of the animal. Ascorbic acid functions as an oxygen
acceptor in several mixed-function oxidase systems. Rowe
et al. reported that ascorbic acid had an eﬀect on collagen
synthesis by human diploid ﬁbroblasts and played a role
as a growth-promoting factor for many cell types [96].
The use of ascorbic acid for hMSC culture seems to be
a matter of debate. Gronthos and Simmons demonstrated
that ascorbic acid was a critical component under serum-
free conditions for supporting the formation of CFU-F
colonies in primary cultures of human BM cells [97]. We
and others also demonstrated that ascorbic acid promoted
hMSC growth [76, 98]. Moreover, it was observed that
the lack of ascorbic acid in medium signiﬁcantly reduced
osteogenic potential of hMSCs [76]. On the other hand,
ascorbic acid has typically been used as a supplement in
some MSC diﬀerentiation media. Mimura et al. reported
that ascorbic acid increased osteoblastic marker expression
in hMSCs grown in a serum-free condition, and thus the
authorsremovedthiscomponentfromtheirdeﬁnedmedium
formulation [85]. It should be noted that ascorbic acid is
very labile under cell culture conditions [99]; therefore, care
should be taken when this substance is used in cell culture.
Inorganic Salts. The salts that are included in most media
are those of Na+,K +,M g 2+,C a 2+,C l −,S O 4
2−,P O 4
3−,a n d
HCO3
−, and they play several functions. The salts primarily
contribute to retaining the osmotic balance of the cells.
The osmolality of most cell culture media is approximately
300mOsm/kg, and this represents an optimal value for
most cell lines. It has been shown that many cell lines
tolerate variation of approximately 10% of this optimal
value, and thus care should be taken when extra salts are
added into a medium [45]. Divalent cations, particularly
Ca2+, are required by some cell adhesion molecules, such
as the cadherins. Ca2+ also acts as an intermediary in signal
transduction, and the concentration of Ca2+ in the medium
can have an inﬂuence on cell proliferation or diﬀerentiation.
Na+,K +,a n dC l − regulate membrane potential, while SO4
2−,
PO4
3−, and HCO3
− have roles as anions required by the
matrix and nutritional precursors for macromolecules, as
well as regulators of intracellular charge. HCO3
− also plays
ar o l ea sab u ﬀer and its concentration is determined by the
concentration of CO2 in the gas phase [100].
Trace Elements. In addition to the inorganic salts, other
inorganic elements, such as Mn2+,C u 2+,Z n 2+,M o 6+,V a 5+,
Se8+,F e 2+,C a 2+,M g 2+,S i 4+,N i 2+ are present in serum in
trace amounts. These substances are referred to as trace
elements and are included in most medium formulations.
Although the role of these trace elements has been only
partially elucidated, it has been demonstrated that many of
these elements act as enzyme cofactors and are essential to
the survival and growth of most cells [45, 101]. For instance,
selenium is well recognized as an activator of glutathione
peroxidase, a key enzyme essential for detoxifying cytotoxic
oxygen radicals, and has been considered as an essential trace
element for many cell types in culture [92, 102, 103]. It
was also observed that selenium increased the proliferation
of hMSCs from AT [104]. In contrast, numerous reports
demonstrated that selenium suppressed cell proliferation in
culture and induced cytotoxicity [105]. In our study, the
addition of selenium into a serum-based medium reduced
the colony-forming ability of hMSCs [76]. Considered
together, the eﬀect of selenium on hMSC expansion seems
to depend on culture conditions or cell sources.
4.1.2. Nonnutrient Factors. Beyond the nutrients, the growth
of mammalian cells requires additional substances (provided
from serum or other sources). These nonnutrient factors,
including growth and attachment factors and hormones,
generally function in regulatory roles on cellular diﬀerenti-
ation as well as growth and proliferation. These regulatory
factors are not included in most basal media and are
frequently supplemented to serum-free media. Often, the
requirements of nutrients for the growth of cells of interest
could be satisﬁed by selecting appropriate deﬁned basal
media; therefore, identifying growth-stimulating regulatoryStem Cells International 11
factors has typically been the key subject in the develop-
ment of serum-free media. Much eﬀort has been made to
investigate the eﬀect of cytokines and growth factors on
hMSC growth. Many reports showed that bFGF promotes
the proliferation of hMSCs [76, 106–109]. TGF-β1 is also
known to support hMSC proliferation in combination
with other growth factors [85, 106]. It is important to
note that TGF-β1 alone showed a growth-inhibitory eﬀect
on hMSCs, while demonstrating a signiﬁcant degree of
synergistic eﬀect with bFGF [76] .T h ei m p a c to fP D G Fo n
hMSCs is controversial. Several studies reported that PDGF
enhanced the proliferation of MSCs from human and animal
BM [77, 97, 106]. Moreover, PDGF-enriched plasma or
platelet lysate has been shown to support the isolation and
expansion of hMSCs. In contrast, our group observed that
PDGF reduced considerably the colony-forming property
of hMSCs [76]. It is presumed that the contradictory data
are due, at least in part, to diﬀerent modes of interactions
with diﬀerent factors present in diﬀerent culture conditions.
O t h e rg r o w t hf a c t o r s ,s u c ha sE G F ,A c t i v i nA ,a F G F ,a n d
FGF4, have also been shown to promote hMSC prolifera-
tion (e.g., [76, 110, 111]); however, their eﬀects could be
masked in the presence of more potent factors (e.g., bFGF)
[76].
Binding proteins such as albumin and transferrin are
commonly added to serum-free media. Parker et al. reported
that the absence of albumin in their serum-free formu-
lation reduced hMSC growth [80]. Supplementation of
key hormone components into serum-free media is also
crucial. We observed no stimulatory eﬀects of insulin and
progesterone under FBS-based conditions in our study [76].
Nonetheless, these components showed growth-promoting
eﬀects for many cell types in serum-free condition [112].
Hydrocortisone has been shown to increase the proliferation
of adherent human BM cells [113]. It has also been
demonstrated that dexamethasone, a synthetic reagent of
ﬂuoridated hydrocortisone, is an essential component in
serum-free medium for the growth of CFU-F colonies in
primary cultures of human BM cells [97]. Interestingly, our
experimentsshowedthatthesupplementationofhydrocorti-
sone into an FBS-containing medium signiﬁcantly inhibited
cell proliferation and caused a change in cell morphol-
ogy from spindle-shaped to cuboidal (data not shown);
however, this hormone was found to be a key component
in our serum-free media for hMSC growth, displaying
a considerable combined eﬀect with fetuin, particularly
in primary culture [76]. This indicates that the eﬀect of
hydrocortisone is highly dependent upon culture conditions.
Fetuin, a major plasma glycoprotein, has been used as a
requirement for serum-free primary cultures of hMSCs and
other cell types such as mouse ﬁbroblast and epithelial
cells [76, 114]. Heparin, a glycosaminoglycan that typically
acts as an anticoagulant factor, has been shown to have
proliferative or antiproliferative eﬀects on various cell types
[115, 116]. Addition of heparin into culture media led to
a reduced growth of hMSCs from AT and BM [66, 76].
In contrast, Mimura et al. reported the growth-enhancing
eﬀect of heparin on a genetically modiﬁed hMSC line
[85].
4.1.3. Other Variables. For successful cell cultures, it is
also important to control other key variables, particularly
when serum-free media are used. Beyond the nutrients
and nonnutrient factors, medium pH, osmolality, and
partial pressure of dissolved gases in culture are important
for cell growth. In addition, environmental conditions,
including temperature and the nature of culture surface,
have signiﬁcant impacts. Finally, culture techniques, such as
trypsinization and passaging protocol, are also important
factors. Review of these variables on hMSCs in serum-free
conditions is out of the scope of this paper.
4.2. Serum Components and Functions. Media for the culture
of stem cells must provide all the essential requirements for
cell survival and growth while maintaining their undiﬀer-
entiated characteristics. These requirements (both deﬁned
and undeﬁned) are normally provided by using serum in
hMSC cultures. Serum is an extremely complex ﬂuid, which
is prepared by deﬁbrination of plasma. It contains a broad
spectrum of biological factors (Table 1) having physiologi-
cally balanced growth-promoting, growth-inhibiting, and/or
diﬀerentiation-inducing activities [101, 112]. The important
componentsofserumandtheirmainfunctionsareasfollows
[45, 48, 101, 112]:
(i) growth factors (e.g., PDGF, EGF, FGF, IGF-1, IGF-
2) promoting cell proliferation: some of these factors
may be cytostatic and induce diﬀerentiation;
(ii) components of base membrane (e.g., ﬁbronectin)
andotheradhesionfactors(e.g.,fetuinandhydrocor-
tisone,particularlypresentinfetalserum)supporting
cell attachment and spreading;
(iii) trace elements (e.g., selenium), minerals, vitamins
(e.g., ascorbic acid), lipids, and hormones (e.g.,
insulin, hydrocortisone): many of these are bound
to carrier proteins, stimulating cell growth, and are
involved in many other biological activities;
(iv) othernutrients(e.g.,aminoacids,nucleosides):some
of these are present in solution and the others are
bound to proteins. These nutrient components are
largely included in basal media, but serum also
provides necessary nutrients that may not be present
in basal media or may not be present in suﬃcient
amounts to promote growth;
(v) binding proteins (e.g., albumin, transferrin) carrying
minerals, vitamins, lipids, hormones, and other
nutrients: these proteins play a role to stabilize and
modulate the activity of the components which they
bind;
(vi) buﬀer (e.g., albumin and others) modulating pH: the
role of serum for increasing the buﬀering capacity is
particularly important where the seeding density is
low (e.g., cell cloning experiments);
(vii) protease inhibitors (e.g., α2-macroglobulin) neutral-
izing proteases: these antiproteases protect cells from
damage caused by their exposure to proteases such as
trypsin used in the passaging procedure or proteases12 Stem Cells International
Table 1 :C o n s t i t u e n t so fs e r u m[ A d a p t e df r o m[ 112]].
Range of Range of
Constituent concentration Constituent concentrationa
Proteins and polypeptides 40–80mg/mL Polyamines: 0.1–1.0μM
Albumin 20–50mg/mL Putrescine, Spermidine
Fetuinb 10–20mg/mL
Fibronectin 1.0–10μg/mL Urea 170–300μg/mL
Globulins 1.0–15mg/mL
Protease inhibitors: 0.5–2.5mg/mL Inorganics 0.14–0.16M
αl-antitrypsin, Calcium 4.0–7.0mM
α2-macroglobulin Chlorides 100μM
Transferrin 2.0–4.0mg/mL Iron 10–50μM
Potassium 5.0–15mM
Growth factors: Phosphate 2.0–5.0mM
EGF, PDGF, IGF1 and 2, 1.0–100ng/mL Selenium 0.01μM
FGF, IL-1, IL-6 Sodium 135–155mM
Zinc 0.1–1.0μM
Amino acids 0.01–1.0μM
Hormones 0.1–200nM
Lipids 2.0–10mg/mL Hydrocortisone 10–200nM
Cholesterol 10μM Insulin 1.0–100ng/mL
Fatty acids 0.1–1.0μM Triiodothyronine 20nM
Linoleic acid 0.01–0.1μM Thyroxine 100nM
Phospholipids 0.7–3.0mg/mL
Vitamins 0.01–10μg/mL
Carbohydrates 1.0-2.0mg/mL Vitamin A 10–100ng/mL
Glucose 0.6–1.2mg/mL Folate 5.0–20ng/mL
Hexosamine 0.6–1.2mg/mL
Lactic acid 0.5–2.0mg/mL
Pyruvic acid 2.0–10μg/mL
aThe range of concentrations is approximate and is intended to convey only the order of magnitude.
bIn fetal serum only.
released by the cells during culture. They may also
p r o m o t ec e l la t t a c h m e n t ;
(viii) protection factors (e.g., albumin and others) con-
tributing to viscosity and thus protecting circulating
cells from mechanical damage (e.g., shear stress
induced by pipetting or agitation in suspension cul-
ture): these elements are considered less important
in monolayer culture, but they may be important in
protecting trypsinized cells from the pipetting;
(ix) antitoxins: these factors bind and neutralize toxins.
When serum is omitted from culture media, it is impor-
tanttoﬁndsubstitutes(i.e.,alternativemediumsupplements
together with appropriate culture protocols) that can replace
the serum functions essentially required for cell survival and
proliferation. In most cases, the requirements are multiple,
and thus it is necessary to investigate the eﬀects of both
nutritional factors and regulatory factors. Typically, native
proteins puriﬁed from serum (e.g., albumin, insulin, trans-
ferrin, fetuin) and synthetic substances (e.g., recombinant
growth factors) are added into serum-free formulations.
The requirements of these and other supplements vary
greatly, depending on the cell type being studied and the
basal medium selected. Moreover, it is very important to
employ appropriate culture protocols (e.g., culture surface,
trypsinization) to properly examine the eﬀects of the supple-
ments.
4.3. Proposed Approaches for Deﬁned Serum-Free Medium
Development. Typically, to select basal media, growth factors
and other medium supplements in a logical way (i.e.,
understandingserumfactorsandtheirfunctions,andﬁnding
related information from the literature) and then to perform
trial and error experiments may be the only method to
identify the best candidates. The most well-known funda-
mental strategies for the development of a new serum-free
medium were proposed in the 1960s and 1970s by separate
groups.Togetherwiththeseclassicalmethods,somepractical
approaches are summarized below.
4.3.1. Ham’s Approach. Ham developed a method for sub-
stantially reducing (or eliminating in certain cases) the
amount of serum in a medium. This approach is based onStem Cells International 13
the careful manipulation of media components and culture
conditions (i.e., by modifying the deﬁned constituents of
an existing medium formulation and a culture protocol
previously developed for a related cell type without adding
growth factors) in order to provide cells with an optimal
nutrient balance [92]. In other words, the adjustment of
concentrations of the nutrients to optimum values and
the manipulation of culture protocols enables signiﬁcant
reduction of the concentration of serum proteins, although
it is unknown what functions of serum are exactly replaced.
It has been demonstrated that variables whose modiﬁcation
has contributed to reducing the requirement for serum
proteins include (i) the nature of the culture surface, (ii)
the type of trypsinization procedure, (iii) buﬀering, (iv) pH,
(v) osmolarity, (vi) the availability of all nutrients, and (vii)
quantitative adjustment of their concentrations. The basic
concept of Ham’s approach to reduce serum in the medium
is (i) to reduce the amount of serum to a level that restricts
growth and then (ii) to look for changes in the medium or
culture conditions that will improve growth. During their
work, Ham and colleagues found it important to reexamine,
at lower serum concentrations, those factors that had no
eﬀect on growth at higher amounts of serum.
Procedure of Ham’s Approach. In the attempt to replace the
functions of serum with the quantitative adjustment of the
nutrient concentrations and culture conditions, Ham and
colleagues used the following approach.
(1) The amount of serum is reduced to a level that yields
suboptimal growth in a medium. The medium is
selected, based on its performance for the growth of
a related cell type.
(2) To identify those components whose quantitative
adjustment is the most limiting to growth with the
low concentration of serum, the eﬀect of increasing
and decreasing the concentration of each individual
c o m p o n e n to ft h em e d i u mb y5o r1 0t i m e si st e s t e d .
(3) Thecomponentthathasthegreatesteﬀectinthispre-
liminary survey is then tested over a wide range
of concentrations. In this step, a typical growth-
response curve is generated and divided into three
parts as follows:
(i) The ﬁrst is a direct growth response, in which
growth improves as the nutrient concentration
is increased until a saturation value is reached.
(ii) The second is a plateau where further increases
in the nutrient concentration have no eﬀect on
growth.
(iii) Thethirdisatoxicresponseinwhichincreasing
the nutrient concentration has a detrimental
eﬀect on growth.
Figure 3 shows a schematic growth-response curve typical
for most components, although the growth stimulation to
certain factors is biphasic in rare cases [92]. At the upper
end of the curve in Figure 3, serum proteins have the ability
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Figure 3: Idealized growth response curve versus nutrient concen-
tration illustrating the procedure for determining the “optimum”
concentration of a nutrient. The range of concentrations that
support optimum growth (referred to as a “plateau”) is determined,
and its midpoint on the plot is selected as the concentration to be
used in future media (Adapted from [92]).
to protect cells from the inhibitory eﬀect of excess amounts
of nutrients. At the lower end of the curve, a large amount
of serum proteins permit cells to grow at concentrations
of essential nutrients that would be inadequate with lesser
amounts of serum protein. Each time that such a titration is
performed, the midpoint of the plateau region on the growth
response curve is selected as the optimum concentration for
useinfuturemedia.Thisprocessisusefultokeeptheselected
nutrient concentration as far separated as possible both from
nutritional inadequacy and from toxicity (i.e., the lower end
and upper end, respectively, of the growth-response curve in
Figure 3).
(4) Once the quantitative adjustment improves growth,
the concentration of serum is reduced until it again
becomes limiting.
(5) At the readjusted lower concentration of serum, the
next most critical component whose concentration
needstobeadjustedisdeterminedrepeatingthesteps
2a n d3 .
(6) These steps above are repeated until serum is reduced
to the minimum level or is completely eliminated in
certain cases of transformed cells.
Based on the results obtained using this approach, Ham
and colleagues classiﬁed the growth-promoting functions
of serum into two operational categories, “replaceable”
and “nonreplaceable”. The replaceable category consists of
those functions of serum that could be replaced by making
changes in the deﬁned portion of the medium or in the
culture conditions. In contrast, the nonreplaceable functions
are those that could not be replaced using this approach.
Ham’s group reported that serum was completely eliminated
by using their method for the growth of some cell lines
including certain normal cells; however, it was later found
that these cell lines underwent subtle transformations, which
enabled their growth in the absence of serum proteins [117].14 Stem Cells International
Using this approach, Ham’s group was able to formulate
a variety of basal media, such as Ham’s F12 and MCDB
series, providing optimal nutrient balances to certain cell
types. These medium formulations supported the clonal
growth of many speciﬁc cell lines in the presence of a
minimized amount of serum. However, this approach is
extremely labor intensive and time consuming. Further,
as the “nonreplaceable functions” of serum could not be
replaced for the growth of normal cells using this approach,
externally supplied growth-promoting substances, in the
form of dialyzed serum, puriﬁed fractions from serum, or
synthetic materials, should still be provided to the cells to
obtain satisfactory growth even with the optimized media
and culture conditions.
4.3.2. Sato’s Approach. In contrast to Ham’s approach, which
is analytical in nature, Sato and colleagues developed a syn-
theticmethodforthereplacementofseruminculturemedia.
This approach was based on attempts (i) to understand what
roles serum play for the maintenance and growth of cells in
cultureandthen(ii)tosupplementanexistingbasalmedium
formulation with a combination of key hormones and
growth factors mimicking the growth-stimulatory function
of whole serum while restricting the manipulation of the
basal media components [48]. For example, one of the main
functions of serum is to provide a mixture of hormones,
which is stimulatory for cell growth. In order to identify the
activeadditives,anarrayoffactorsistestedundersuboptimal
conditions—for example, at lowered serum concentrations,
as described below.
Procedure of Sato’s Approach
(1) The growth promoting capacity of serum is ﬁrst
lowered to a level that yields suboptimal growth by
reducing the concentration of serum, in order to see
a stimulation of growth when various factors under
investigation are added to the medium.
(2) Upon understanding what functions serum serve
for cells in culture and the speciﬁc requirements of
nutrients and nonnutrient growth factors, a large
array of factors is selected and tested under the
suboptimal conditions.
( 3 )A sa c t i v ef a c t o r sa r ei d e n t i ﬁ e d ,t h es e r u mc o n c e n t r a -
tion is further lowered and the search continued.
Through their extensive work on many cell types,
Sato’s group identiﬁed various key essential supplements,
hormones, binding proteins, lipids, trace elements, and
attachment factors, required for addition to basal medium.
In particular, they demonstrated that insulin, transferrin,
and selenium were essential for the growth of most cells
while hydrocortisone and EGF were additionally needed
for certain cell types. Using their approach, Sato and
colleagues were able, for a number of diﬀerent types of
cells, to replace serum with hormones and growth factors
while leaving the basal medium essentially unchanged.
However, Sato’s approach is still labor intensive and time
consuming.
4.3.3. Top-Down and Bottom-Up Approaches. Considered
as more practical approaches, top-down and bottom-up
approaches can be used eﬀectively for the development of a
new serum-free medium formulation for the growth of a cell
population of interest [45].
Top-Down Approach. This approach involves employing an
existing medium formulation for a similar cell type, and
identifyingstimulatorycomponentsinthepresenceofserum
for the growth of the target cells. This process proceeds
as the concentration of serum is gradually reduced. This
concept evolved from the premise that a cell type, which
belongs to a group of cells with similar characteristics,
often requires the same combination of growth factors
for growth. When this approach is used, care should be
taken to identify the existence of any cytotoxic or growth-
inhibitory components in the medium for the cells being
studied.
Bottom-Up Approach. This approach involves ﬁrst selecting
an appropriate basal medium (e.g., a medium used for the
growth of a related cell type) and then screening various
selected exogenous factors for their growth-stimulatory
eﬀects. Since only the active components required for the
growth of cells of interest are added into the medium,
the ﬁnal formulation will represent an eﬃcient and easily
amendable medium. However, this approach is likely to
be labor-intensive and time-consuming. Further, since the
screening of factors being examined is performed in the
absence of serum, the critical functions of serum required to
see their eﬀects should be carefully considered and satisﬁed
by alternative means (e.g., well-controlled physiochemical
parameters, treatment of culture surface, trypsinization and
passage protocols), because normally the serum-free basal
medium does not provide such functions.
We would like to point out that there is no universal
guideline for screening selected medium additives towards
the development of a new medium, and thus it is impor-
tant for investigators to understand the advantages and
disadvantages of all the approaches previously proposed
and then to exploit beneﬁcial features of each approach for
designing their own strategies in a rational, eﬀective manner.
As an example, in our study for hMSC serum-free medium
development [76], we selected various medium ingredients
(basal media, extra nutrients, binding proteins, buﬀering
agents, hormones, vitamins, and growth and attachment
factors) based on the understanding of cell culture require-
ment including the role of serum constituents. And then
the selected factors were examined in a sequential man-
ner, employing some useful suggestions of each approach
described earlier, in order to determine chronologically
their impact on proliferation, attachment, and isolation
of hMSCs (Figure 4). In addition, an eﬀective serum-free
medium development can be achieved by considering other
important issues as discussed below.Stem Cells International 15
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Figure 4: An overview demonstrating a process for the development of a deﬁned serum-free medium for hMSCs. (a) To replace ill-deﬁned
serum with deﬁned supplements, a variety of medium constituents, including basal media, additional nutrients (e.g., lipids and vitamins),
binding proteins, physiochemical reagents (e.g., buﬀer), hormones, growth factors, and attachment factors were selected. (b) A sequential
strategy was designed for screening eﬀectively the selected basal media and medium additives to develop a deﬁned serum-free condition that
supports the isolation and expansion of hMSCs [76].
4.4. Considerations for the Development of
a New Serum-Free Medium
4.4.1. Selection of Materials and Testing Methods
Selection of Basal Media. hMSCs are typically cultured
in Dulbecco’s Modiﬁed of Eagle’s Medium (DMEM) or
Minimum Essential Medium Alpha (αMEM) with the sup-
plementation of FBS. However, whether these basal media
are appropriate for serum-free culture should be critically
considered for the cell type being investigated, because
each basal medium has been developed or optimized for
a speciﬁc application. For example, Ham’s F12, which was
developed for the clonal growth of Chinese Hamster Ovary
cells in low serum, contains a wide range of ingredients at
low concentrations, while DMEM, which was optimized at
higher cell densities for viral propagation, contains fewer
constituents but at high concentrations [45]. For this reason,
a 1:1 mixture of DMEM and Ham’s F12 has been used
for the culture of many cell types with serum or as a basis
for serum-free media, since this combination provides a
reasonable compromise between high concentrations and a
wide range of ingredients. The DMEM/F-12 mixture has
been employed as a basal medium for the development of
serum-free media for hMSCs [76, 80].
Selection of Factors to Be Tested. Recent trends towards
the development of serum-free media for the growth of a
cell type often exclusively focus on the eﬀect of “regula-
tory growth factors” such as peptide growth factors and
hormones. When an established serum-free medium exists
for those cells or a closely related cell type, this approach
represents a reasonable method, because this type of study
is more likely to be characterized as a medium optimiza-
tion or modiﬁcation process, rather than a “signiﬁcant”
development. When such a medium is not available, the
medium development process will be more extensive and
complicated. In this case, together with the wide-ranging
investigation ongrowth-promoting growthfactorsandother
medium supplements, considerations should also be placed
on other properties of cells (e.g., attachment, in particular
in primary culture). In this regard, an understanding of
serum functions and related constituents is important to
select candidates to be examined.16 Stem Cells International
Culture Protocol for Screening Factors. In the development
of serum-free media for anchorage-dependent cells, as
described earlier, conventional approaches for screening
growth factors include the use of serum with gradual
reduction of its content in media to (a) provide unidentiﬁed
adherent proteins for facilitating cell attachment to the
substrate and (b) support suﬃc i e n tg r o w t hl e v e l st oo b s e r v e
meaningfully the impact of the additives [48, 92]. However,
this procedure is very labor intensive and time consuming.
As a more practical approach, it has been suggested to plate
the cells initially in serum-containing medium, remove the
medium after the cells attach, and screen the factors in
serum-free medium [48]. It was further recommended that
this protocol would work best in the presence of insulin
and transferrin because these two components are required
for most cell types and their presence is necessary for the
appearance of a stimulatory eﬀect of other factors [48]. This
screening protocol has also been eﬀectively employed for a
serum-free medium development for hMSCs [76].
Necessity of Reexamination of Factors. Through their exten-
sive work on medium development, both Ham and Sato
demonstrated that the composition of a medium formula-
tioncouldmaskeﬀectsofcertainfactorsunderscreeningthat
could reveal their impact at diﬀerent medium compositions
or their concentrations [48, 92]. For example, it was shown
that some factors, such as transferrin, were not stimulatory
until the serum concentration was substantially reduced
[48]. This is because some serum components at high con-
centrations covered the eﬀect of transferrin, which became
unmasked at the decrease of their concentrations to certain
levels. Conversely, eﬀects of certain factors under screening
could also be unrevealed in the absence of some medium
components. Therefore, both Ham and Sato proposed that
the examination of selected factors and the adjustment
of their concentrations to optimum values be done in a
stepwise manner at progressively deﬁned compositions and
concentrations of the medium formulation and that certain
factors having no eﬀects at a condition be reevaluated under
a revised screening condition.
Synergistic Eﬀects. Growth factors often act synergistically
or additively with each other or with other hormones. In
this regard, statistical approaches have been widely used
to investigate speciﬁc interactions between growth factors
under screening. This method will be powerful when a
good screening medium, which includes requirements for
cell maintenance and at least “minimal” growth as well as
attachment, is available to examine eﬀectively the individual
and synergistic eﬀects of the selected growth factors.
Contamination with Other Trace Elements. It is known that
puriﬁed serum proteins, such as albumin, insulin, transfer-
rin, and fetuin, often carry other trace components, which
may aﬀect cell growth. Therefore, it is desirable to use
highly puriﬁed substances or completely deﬁned synthetic
materials, if available, to determine conclusively the eﬀect of
such proteins.
4.4.2. Cell Culture Aspects in Serum-Free Conditions
Cell Handling. Cells grown in serum-free conditions are
more delicate than those grown in the presence of serum and
thus should be handled very gently to minimize cell damage
during the harvesting and passaging procedures.
Buﬀer System of Media. Since the buﬀering function of
serum to modulate pH is omitted in serum-free cultures,
it may be beneﬁcial to further supplement the medium
with a chemical buﬀer such as HEPES, in addition to the
bicarbonate-CO2 system, in order to improve the buﬀering
capacity of the medium. The HEPES concentration could
be increased above 15mM without toxicity for some cell
lines, but it may be necessary to adjust the osmolality of the
medium accordingly [48].
Lack of Detoxifying Substances. As serum proteins that could
bind and neutralize toxic contaminants are not present in
serum-free conditions, its protective, detoxifying activity is
also omitted. Thus, care should be taken in selecting water,
reagents, as well as culture techniques. The level of purity
of water and reagents and the degree of cleanliness of all
apparatus must be very high [45, 48, 112]. In general, basal
media are recommended to be kept at 4◦C no longer than
2 weeks because their constituents are more likely to be
decomposed in the absence of those detoxifying serum com-
ponents. Growth factors and other medium supplements, in
particular labile components such as transferrin, hormones,
and ascorbic acid, should be reconstituted, stored and used
strictly according to the manufacturer’s instruction.
Lack of Protease Inhibitors. The addition of serum to cells
exposed to trypsin during trypsinization neutralizes any
residual proteolytic activity. Protease inhibitors such as apro-
tinin and soybean trypsin inhibitor could be used to replace
this function. However, the level of their antiproteolytic
action and their potential impact on cell growth should be
examined by testing these materials in a dose-dependent
manner in comparison with a control case using serum. In
addition, as an alternative trypsinization protocol, the use
of native trypsin could be replaced by a less detrimental
protease (e.g., recombinant trypsin) for cell harvesting.
Moreover, recombinant trypsin has eﬀectively been used
for hMSC culture in serum-free conditions [84, 87–90].
When recombinant trypsin is used to detach cells from the
substrate, the use of FBS or other trypsin inhibitors may
not be necessary for serum-free culture. In contrast, Hudson
et al. used serum albumin (1%) in PBS to wash cells after
trypsinization with recombinant trypsin [90].
5. Conclusions
Clinical eﬃcacy for the use of hMSCs has been variable and
probably still insuﬃcient for widespread implementation
of hMSC therapies. Enhancing culture protocols may be
a critical issue to meet eﬃcacy endpoints in upcomingStem Cells International 17
clinical studies. Well-formulated chemically deﬁned serum-
free media for hMSC isolation and expansion would greatly
contribute to the achievement of this goal. Towards this
objective, signiﬁcant progress has been made to generate
various medium formulations for hMSC culture in the
absence of ill-deﬁned FBS and human-sourced supplements.
These deﬁned media should be critically evaluated through
in vitro and in vivo analyses and most likely further reﬁned
for optimal performance. In this regard, fully disclosed
formulations should represent important platforms for
enhancing the therapeutic potential of hMSCs. We also
emphasize thatthe identiﬁcation of key elements towards the
development and optimization of serum-free media should
follow rational, systematic approaches in order to maximize
the possibility of ﬁnding their true eﬀects on hMSCs. All the
issues reviewed herein should thus be considered seriously
when medium development and optimization studies are
carried out.
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